Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00405938 · ClinicalTrials.gov registry record · Phase 2
Bevacizumab Given With Either Anastrozole or Fulvestrant With Trastuzumab for Postmenopausal Metastatic Breast Cancer
A Phase 2 study of Breast Cancer and Breast Neoplasms, sponsored by SCRI Development Innovations.
- Completed
- Registry status
- Phase 2
- Development phase
- 79
- Enrollment target
- 11
- Study locations
NCT00405938 is a Phase 2 study of Breast Cancer and Breast Neoplasms that has completed, run by SCRI Development Innovations. The registered enrollment target is 79 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (97% lower). The trial reports 11 study locations across 7 states.
The verdict
NCT00405938, a Phase 2 study of Breast Cancer and Breast Neoplasms, has completed, sponsored by SCRI Development Innovations.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 79 participants
- Enrollment target
- 11
- Study locations
Study Summary
This is a phase II trial combining bevacizumab with either fulvestrant or anastrozole with trastuzumab in the treatment of metastatic breast cancer in postmenopausal women. It is hoped that these combinations will keep the cancer from growing and spreading further.
Conditions Studied
Interventions
- DRUG Bevacizumab
- DRUG Anastrozole
- DRUG Fulvestrant
Study Locations (11)
Florida
- Florida Cancer Specialists - Fort Myers
- Integrated Community Oncology Network - Jacksonville
- Florida Hospital Cancer Institute - Orlando
Georgia
- Northeast Georgia Medical Center - Gainesville
- Wellstar Cancer Research - Marietta
Tennessee
- Chattanooga Oncology & Hematology Associates - Chattanooga
- Tennessee Oncology, PLLC - Nashville
Kentucky
- Graves-Gilbert Clinic - Bowling Green
Louisiana
- Baton Rouge General Medical Center - Baton Rouge
Missouri
- St. Louis Cancer Care - Chesterfield
Montana
- Sletten Cancer Institute - Great Falls
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 79 participants |
| Start Date | 2006-11 |
| Est. Completion | 2011-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00405938
The ClinicalTrials.gov registry entry for NCT00405938 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 79 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (97% lower). The listed sponsor is SCRI Development Innovations, which has 146 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Breast Cancer appearing as the primary indexed condition, and to 3 interventions - of which Bevacizumab is the first listed.
NCT00405938 reports 11 study locations spanning 7 distinct geographic areas - top geographies include Florida, Georgia, Tennessee.
Frequently Asked Questions
What is clinical trial NCT00405938 about?
NCT00405938 is a clinical study titled "Bevacizumab Given With Either Anastrozole or Fulvestrant With Trastuzumab for Postmenopausal Metastatic Breast Cancer". This is a phase II trial combining bevacizumab with either fulvestrant or anastrozole with trastuzumab in the treatment of metastatic breast cancer in postmenopausal women. It is hoped that these combinations will keep the cancer from growing and spreading further.
What is the current status of trial NCT00405938?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 79 participants. The study started on 2006-11. Estimated completion is 2011-06.
What conditions does trial NCT00405938 study?
This clinical trial studies the following conditions: Breast Cancer, Breast Neoplasms.
What interventions are being tested in trial NCT00405938?
The interventions under investigation include: Bevacizumab (DRUG), Anastrozole (DRUG), Fulvestrant (DRUG).
Who is sponsoring clinical trial NCT00405938?
This trial is sponsored by SCRI Development Innovations, which has 146 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00405938 being conducted?
This trial has 11 study locations across Florida, Georgia, Kentucky, Louisiana, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Sequencing Antibody Drug Conjugates in ER+/HER2 LOW/ULTRA LOW MBC
RECRUITING · Phase 2
-
The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer
RECRUITING · Phase 2
-
Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC
RECRUITING · Phase 2
-
Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial
RECRUITING · Phase 2
-
Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score
RECRUITING · Phase 2
-
Precision Medicine in Action: Phase II Trial of Response Adaptive Ablative Pre-operative SPBI (RAPS) and Non-operative Sentinel Lymph Node Biopsy in Patients With Early-stage ER+ Breast Cancer: RAPS Trial
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.